Imiquimod TLR7 stimulation shows sex-specific immune responses in HIV and non-HIV populations
Research shows immune reactions to imiquimod vary between men and women with HIV
This cohort study evaluated TLR7 stimulation with imiquimod in 1,326 individuals living with HIV and 43 people without HIV. Women living wit…
Women with HIV show different immune reactions to imiquimod than men, suggesting doctors may need to consider biological sex when developing…
Imiquimod costs substantially less than radiotherapy for lentigo maligna in Australian analysis
Study finds topical treatment for lentigo maligna costs far less than radiotherapy
A phase 3 RCT-based cost analysis of 118 patients with lentigo maligna found imiquimod had dramatically lower healthcare system (US$72.50 vs…
Topical cream costs just $72 per patient versus over $2,600 for radiotherapy when treating lentigo maligna, a sun-damaged skin condition.